🇺🇸 FDA

Intelligence Platform

Patents

Browse 41 pharma-relevant US patents (A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 12201719

Combination therapy with semaphorin-4D blockade (SEMA4D) and DC1 therapy

VACCINEX, INC. · Granted Tue Jan 21 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 16 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12070500

Use of semaphorin-4D antibodies in combination with an immune modulating therapy to inhibi

VACCINEX, INC. · Granted Tue Aug 27 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 22 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12006365

Human anti-semaphorin 4D antibody

VACCINEX, INC. · Granted Tue Jun 11 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 06 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12006364

Anti-CD100 antibodies and methods for using the same

VACCINEX, INC. · Granted Tue Jun 11 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 06 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11981730

Anti-CXCL13 antibodies and methods of using the same

VACCINEX, INC. · Granted Tue May 14 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 09 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11859000

Anti-CCR8 antibodies and uses thereof

VACCINEX, INC. · Granted Tue Jan 02 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 28 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11660330

Combination therapy with semaphorin-4D blockade (SEMA4D) and DC1 therapy

VACCINEX, INC. · Granted Tue May 30 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 25 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11597765

Use of semaphorin-4D binding molecules for the treatment of Rett syndrome

VACCINEX, INC. · Granted Tue Mar 07 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11572408

Treatment of cancer with a semaphorin-4D antibody in combination with an epigenetic modula

VACCINEX, INC. · Granted Tue Feb 07 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11534488

Use of semaphorin-4D binding molecules for modulation of blood brain barrier permeability

VACCINEX, INC. · Granted Tue Dec 27 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 22 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11427634

Human anti-semaphorin 4D antibody

VACCINEX, INC. · Granted Tue Aug 30 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 25 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11274149

Anti-CD100 antibodies and methods for using the same

VACCINEX, INC. · Granted Tue Mar 15 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11078295

Use of semaphorin-4D inhibitory molecules with an immune modulating therapy to inhibit tum

VACCINEX, INC. · Granted Tue Aug 03 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 29 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10829550

Polynucleotides encoding anti-CXCL13 antibodies

VACCINEX, INC. · Granted Tue Nov 10 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 05 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10800853

Use of semaphorin-4D binding molecules for treating neurodegenerative disorders

VACCINEX, INC. · Granted Tue Oct 13 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 08 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10526414

Use of anti-semaphorin-4D antibodies in combination with an immune modulating therapy to i

VACCINEX, INC. · Granted Tue Jan 07 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10494440

Use of semaphorin-4D binding molecules to promote neurogenesis following stroke

VACCINEX, INC. · Granted Tue Dec 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10385136

Use of semaphorin-4D binding molecules for treating neurodegenerative disorders

VACCINEX, INC. · Granted Tue Aug 20 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 15 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10301393

Methods of treating multiple sclerosis using anti-CD20 antibodies

VACCINEX, INC. · Granted Tue May 28 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 23 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10111950

Modified glycolipids and methods of making and using the same

VACCINEX, INC. · Granted Tue Oct 30 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 25 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9963504

Anti-CXCL13 antibodies and methods of using the same

VACCINEX, INC. · Granted Tue May 08 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 03 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9890213

Methods for the treatment of B cell-mediated inflammatory diseases

VACCINEX, INC. · Granted Tue Feb 13 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 08 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9828435

Use of antibodies or antigen-binding fragments thereof that specifically bind semaphorin-4

VACCINEX, INC. · Granted Tue Nov 28 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 23 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9790271

Methods for increasing immunoglobulin A levels

VACCINEX, INC. · Granted Tue Oct 17 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 12 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted